Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02002598 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
A Phase 1 study, sponsored by Suzanne Lentzsch, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02002598 is a Phase 1 study that was terminated before completion, run by Suzanne Lentzsch, MD. The registered enrollment target is 23 participants.
The verdict
NCT02002598, a Phase 1 study, was terminated before completion, sponsored by Suzanne Lentzsch, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma (MM).
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-11 |
| Est. Completion | 2023-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02002598
The ClinicalTrials.gov registry entry for NCT02002598 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzanne Lentzsch, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02002598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02002598 about?
NCT02002598 is a clinical study titled "Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma". This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma (MM).
What is the current status of trial NCT02002598?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-11. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT02002598?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT02002598?
This trial is sponsored by Suzanne Lentzsch, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.